AIM Market’s Top Guns6 Jul 2022 23:10
There can’t be another company on AIM with a BOD and senior management team with this much quality.
They only have about £25 million left in the bank but they are keeping this top team motivated.
They keep adding top talent
Avacta then moves a whole division to a new HQ in London. (Is a move of just 60 miles prudent with their cash flow and ongoing clinical trial costs.)
50% of the following team were added after AVA6000 trial started.
They have recruited some of the worlds most renowned oncology talent, do you think they would still be around if this trial wasn’t showing very positive results so far.
Remember if precision fails Avacta would be relying on Affimers to target cancer, which would be years away.
This team would start to leave this company.
Avacta couldn’t afford to keep them until affimers come through.
But what is happening they continue to recruit even IP lawyers.Plus all the clues.
Aug 21.Trial starts 1st patient dosed with AVA6000.
Appointment of Dr Fiona McLaughlin as Chief Scientific Officer.
SDMC meets twice trial continues.
Sep 21.The three new members of the SAB are Professor James Spicer MB., BA., PhD., FRCP, Professor Krishnan Komanduri, MD, and Dr Ste´phane Champiat MD, PhD.SDMC meets twice trial continues.
Nov 21.FDA Approval of its Investigational New Drug (IND) Application for AVA6000.SDMC meets twice trial continues.
Jan 22.Avacta Selects Second pre|CISIONTM Pro-drug Candidate.SDMC meets twice trial continues.
Feb 22.Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin.
AS and Fiona McLaughlin announce remarkable consistent data and that biopsies will be performed even though they are not needed for this part of trial.
Mar 22.Top American Oncologist Christina Coughlin joins Avacta board.Avacta sells Animal health division.
April 22.Avacta presents preclinical data on AVA6000 at AAC
Glasgow starts recruiting with Sheffield and Newcastle and USA also getting ready to recruit patients.
May 22.Avacta establishes new Therapeutics headquarters at Scale Space,White City London
Jupiter starts to reduce their short.
June 22.SDMC meets twice trial continues.
Avacta Announces Dose Escalation 2.
AVACTA BOD.
Alastair Smith. Chief Executive Officer.
Tony Gardiner. Chief Financial Officer.
Eliot Forster. Non Executive Chairman.
Trevor Nicholls. Non Executive
Paul Fry. Non Executive
Mark A. Goldberg, MD.
Christina Coughlin. Non Executive Director.
Avacta Senior Team.
Neil Bell
Chief Development Officer, Therapeutics
Dr. Mike Owen
Scientific Advisory Board
Professor James Spicer MB., BA., PhD., FRCP, Professor Krishnan Komanduri, MD,
Dr Ste´phane Champiat MD, PhD.
Fiona McLaughlin
Chief Scientific Officer
Diagnostics DIvision
David Wilson
Commercial Director,
Matt Johnson
Chief Scientific Officer,
Marc Green Development
Gemma WilsonHeadQA/RA
Adrian Ruskin Ops director
Avacta BOD’s must be sitting on 4 Aces or a royal flush and kno
Sign In
Follow the stocks
